Navigation Links
NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa
Date:9/22/2010

About Orexo

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. Orexo is developing proprietary products based on its proven reformulation technologies, targeted at the Specialty Pharmaceutical market. Orexo intends to commercialise some of these products itself in one or more major markets. Its development activity builds on Orexo's core competences in R&D, which have previously resulted in several successful products, currently out-licensed through worldwide partnership agreements to larger pharmaceutical companies.

Today, Orexo has four products on the market of which Abstral™ is a leading brand for the treatment of breakthrough pain in cancer patients in most of Europe. Orexo also has three significant partnerships with major pharmaceutical companies for research and development programs: discovery stage collaborations with Ortho-McNeil Janssen and Janssen Pharmaceutica in respiratory inflammation and with Boehringer Ingelheim for pain, both within the arachidonic acid cascade and a clinical stage development agreement with Novartis in gastrointestinal disorders. Orexo's head office is located in Uppsala, Sweden.

More information can be found at www.orexo.com.


'/>"/>
SOURCE NewBridge Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ... of injectable drug delivery systems, today announced the launch ... The new site includes additional products, videos, features, blogs ... regular basis. Mr. Alan Shortall , ... leader for injectable drug delivery systems, we have created ...
(Date:6/18/2013)... 2013  Specialty Coating Systems is pleased ... coating technologies: SCS microRESIST™ Antimicrobial Parylene Technology. ... with antimicrobial properties to effectively eliminate harmful ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... continue to pose a challenge to hospitals ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... 24, 2011 Omnicell, Inc . (Nasdaq: ... supply chain management solutions to healthcare facilities, today announced ... GS1 standards. GS1 is an international association ... and solutions to improve the efficiency and visibility of ...
... Calif., March 24, 2011 Molecular Devices, Inc. and ... drug discovery tools and solutions, have signed an agreement ... ion channel and GPCR cell lines on a non-exclusive ... will sell ChanTest,s ion channel and GPCR cell lines ...
Cached Medicine Technology:Leading Hospitals Committed to Healthcare's Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management 2Leading Hospitals Committed to Healthcare's Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management 3Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 2Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 3
(Date:6/18/2013)... As obesity rates sky rocket in the United ... during childbirth comes as no shock. Forceps are surgical equipment ... she is unable to do so herself and although they ... rates of complication for both the mother and the baby. ... and child, forceps births add to the pressure of healthcare ...
(Date:6/18/2013)... Senior drug regulatory officials from mainland China ... discuss—for the first time in the U.S.—the need for more ... regulatory process in a timely manner. Representatives from the Taiwan ... best practices and processes in drug review during the ... the DIA 2013 49th Annual Meeting . ...
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 Seven-year-old ... to recovery from autism. He receives 40 hours a ... and school shadowing) from the Center for Autism and ... CARD since August, 2008, and has experienced remarkable progress, ... commenting about his environment. Riley’s personal journey through autism ...
(Date:6/18/2013)... Researchers have discovered and mapped the signaling network between ... broken, could cut off cancer cell growth at its ... The University of Texas MD Anderson Cancer Center reported ... well-known cancer drug target, and MCM7, a protein vital ... June issue of Cancer Cell . , "MCM7 ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Two months ago, ... going into surgery for a second session of a silicone ... Miami-Dade County. The treatment was allegedly performed by a mystery ... the board. According to Dr. Bernabe Vazquez of ... receiving such treatments from doctor’s who are not board certified ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... DIEGO, Nov. 12 Halozyme Therapeutics,Inc. (Nasdaq: HALO ... the extracellular matrix, today announced,that it has been selected ... ), effective Monday, November 19. Launched in 1993, ... in May and November and serves as the basis ...
... Inc., (Nasdaq:,QMED) today announced that it has retained ... alternatives. Lazard Middle Market is the middle,market financial ... with Lazard Middle Market Healthcare Services group will ... of Directors. Additionally, Bruce Wesson, QMed,s Chairman, ...
... Ph.D. program in Nurse Education at Mercer, ... R. Timothy Stack and Mercer University President William,D. ... Healthcare,Chair in Nursing that will benefit Georgia Baptist ... by a $2.85 million grant to the,Center for ...
... training to manage the condition , , MONDAY, Nov. 12 ... illness rather than treating it, but a new study ... difference for people with one tough-to-treat condition: fibromyalgia. , ... moderately for four months reported feeling better in a ...
... The Foundation for the Scientific Study of Sexuality (FSSS) ... Rutgers College of Nursing emerita faculty member Beverly Whipple for ... anniversary meeting of the Society for the Scientific Study of ... Vern L. Bullough Award is given by FSSS for the ...
... November 18 at 9 ... AM ET/PT on Discovery Health -, NEW YORK, ... -- one of the most pressing health crises facing,humanity today. Currently, ... number that is expected to explode to 380,million within 20 years. ...
Cached Medicine News:Health News:Halozyme Therapeutics Added to Nasdaq Biotech Index 2Health News:Piedmont Healthcare Funds Nursing Chair at Mercer University 2Health News:Piedmont Healthcare Funds Nursing Chair at Mercer University 3Health News:Exercise Eases Fibromyalgia Symptoms: Study 2Health News:Exercise Eases Fibromyalgia Symptoms: Study 3Health News:Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award 2Health News:Discovery Health Travels the World to Present the Groundbreaking Documentary - Diabetes: A Global Epidemic 2Health News:Discovery Health Travels the World to Present the Groundbreaking Documentary - Diabetes: A Global Epidemic 3Health News:Discovery Health Travels the World to Present the Groundbreaking Documentary - Diabetes: A Global Epidemic 4
PoleStar N-10 is a compact MRI unit that does not require a specially constructed surgery suite. The magnetic field is confined to the volume between the magnet poles and it's immediate neighborhood....
... Adhesive (Bioglue) is a two-component surgical ... albumin (BSA) and glutaraldehyde. The BSA ... bovine spongiform encephalopathy (BSE) free countries ... inactivates viruses. The solutions are dispensed ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: